Consolidated sales of the Ceva Group reached €424m at the end of June 2015, representing growth of 16% and +12% at constant perimeter and exchange rates.
Sales grew in all zones, except Europe which was stable versus last year, with strong performance in North America/Pacific region (+43%), Asia (+38%) and Latin America (+26%).
All species are growing, especially Poultry (+27% globally and +35% on vaccines) and Companion Animals (+13%).
The group delivered an operational result slightly ahead of the budgeted objective and continued to make significant investment in R&D (c.9% of sales).
Marc Prikazsky, Ceva’s Chairman and CEO commented, “The growth of the group remains consistent and ahead of our 2020 business plan. It’s very pleasing to see that our previous investment to develop innovative new technology vaccines is being rewarded with increased business from our poultry customers. We have a significant new pipeline of products to launch, which will further boost our business in companion animals, swine and dairy. ”
July 22, 2015 - Ceva